<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729101</url>
  </required_header>
  <id_info>
    <org_study_id>VONO-103</org_study_id>
    <nct_id>NCT04729101</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants</brief_title>
  <official_title>A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan (20 mg) and Lansoprazole (30 mg) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phathom Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phathom Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of vonoprazan (20 mg) and&#xD;
      lansoprazole (30 mg) following single (Day 1) and multiple doses (Day 7).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Actual">June 26, 2021</completion_date>
  <primary_completion_date type="Actual">June 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Time Gastric pH Above 4 Over a 24-hour Monitoring Period Following Study Drug Administration</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Time Gastric pH Above 4 Over a 24-hour Monitoring Period Following Study Drug Administration</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Gastric pH Over a 24-hour Monitoring Period Following Study Drug Administration</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Gastric pH Over a 24-hour Monitoring Period Following Study Drug Administration</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Day 1 and Day 2 of Periods 1 and 2 (Period = 8 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to the 24-Hour Time Point (AUC0-24)</measure>
    <time_frame>Day 1 and Day 2 of Periods 1 and 2 (Period = 8 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 2 of Periods 1 and 2 (Period = 8 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1 and Day 2 of Periods 1 and 2 (Period = 8 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve During a Dosing Interval (Tau) at Steady State (AUCtau)</measure>
    <time_frame>Day 7 and Day 8 of Periods 1 and 2 (Period = 8 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss)</measure>
    <time_frame>Day 7 and Day 8 of Periods 1 and 2 (Period = 8 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss)</measure>
    <time_frame>Day 7 and Day 8 of Periods 1 and 2 (Period = 8 days)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment A (vonoprazan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.&#xD;
Vonoprazan will be administered via 20 mg oral tablet once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B (lansoprazole)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized to receive vonoprazan (treatment A) and lansoprazole (treatment B) in a two period sequence, following either treatment sequence AB or BA. There will be a washout period of at least 7 days between Period 1 and Period 2.&#xD;
Lansoprazole will be administered via 30 mg oral capsule once daily on Day 1 through to Day 7 in a period, where each period is up to 8 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Treatment A (vonoprazan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Treatment B (lansoprazole)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must fulfill all the following inclusion criteria to be eligible for&#xD;
             participation in the study:&#xD;
&#xD;
               1. Healthy, adult, male or female 18 - 55 years of age, inclusive, at screening.&#xD;
&#xD;
               2. Continuous nonsmoker who has not used nicotine-containing products for at least 3&#xD;
                  months prior to the first dosing and throughout the study, based on participant&#xD;
                  self-reporting.&#xD;
&#xD;
               3. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m^2 at screening.&#xD;
&#xD;
               4. Medically healthy with no clinically significant medical history, physical&#xD;
                  examination, laboratory profiles, vital signs, or electrocardiograms (ECGs), as&#xD;
                  deemed by the principal investigator (PI) or designee.&#xD;
&#xD;
               5. Alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine&#xD;
                  aminotransferase (ALT), and gamma-glutamyl transferase (GGT) &lt; upper limits of&#xD;
                  the clinical laboratory reference range (one recheck is permissible).&#xD;
&#xD;
               6. A female of childbearing potential is either sexually inactive (abstinent as a&#xD;
                  life style) for 28 days prior to the first dosing and throughout the study or is&#xD;
                  using one of the following acceptable birth control methods:&#xD;
&#xD;
                    -  hormonal oral contraceptives, vaginal ring, transdermal patch, or hormone&#xD;
                       releasing intrauterine device for at least 3 months prior to the first&#xD;
                       dosing and with either a physical (e.g., condom, diaphragm, or other) or a&#xD;
                       chemical (e.g., spermicide) barrier method from the time of screening and&#xD;
                       throughout the study.&#xD;
&#xD;
                    -  Depot/implantable hormone (e.g., Depo-Provera®, Implanon®) for at least 3&#xD;
                       months prior to the first dosing and throughout the study.&#xD;
&#xD;
                  In addition, female participants of childbearing potential will be advised to&#xD;
                  remain sexually inactive or to keep the same birth control method for at least 28&#xD;
                  days after the last dose.&#xD;
&#xD;
               7. A female of non-childbearing potential has undergone one of the following&#xD;
                  sterilization procedures at least 6 months prior to the first dosing:&#xD;
&#xD;
                    -  hysteroscopic sterilization;&#xD;
&#xD;
                    -  bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
                    -  hysterectomy;&#xD;
&#xD;
                    -  bilateral oophorectomy;&#xD;
&#xD;
                  or be postmenopausal with amenorrhea for at least 1 year prior to the first&#xD;
                  dosing and follicle stimulating hormone (FSH) serum levels consistent with&#xD;
                  postmenopausal status.&#xD;
&#xD;
               8. A non-vasectomized, male participant must agree to use a condom with spermicide&#xD;
                  or abstain from sexual intercourse during the study until 90 days after the last&#xD;
                  dosing. (No restrictions are required for a vasectomized male provided his&#xD;
                  vasectomy has been performed 4 months or more prior to the first dosing. A male&#xD;
                  who has been vasectomized less than 4 months prior to study first dosing must&#xD;
                  follow the same restrictions as a non-vasectomized male).&#xD;
&#xD;
               9. If male, must agree not to donate sperm from the first dosing until 90 days after&#xD;
                  the last dosing.&#xD;
&#xD;
              10. Understands the study procedures in the informed consent form (ICF), and be&#xD;
                  willing and able to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not be enrolled in the study if they meet any of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Is mentally or legally incapacitated or has significant emotional problems at the&#xD;
                  time of the screening visit or expected during the conduct of the study.&#xD;
&#xD;
               2. History or presence of clinically significant medical or psychiatric condition or&#xD;
                  disease in the opinion of the principal investigator (PI) or designee.&#xD;
&#xD;
               3. History of any illness that, in the opinion of the PI or designee, might confound&#xD;
                  the results of the study or poses an additional risk to the participant by their&#xD;
                  participation in the study.&#xD;
&#xD;
               4. History or presence of alcohol or drug abuse within the past 2 years prior to the&#xD;
                  first dosing.&#xD;
&#xD;
               5. History or presence of hypersensitivity or idiosyncratic reaction to the study&#xD;
                  drug(s), its excipients, related compounds, or lidocaine.&#xD;
&#xD;
               6. Clinically significant gastrointestinal (GI) disorder (e.g., gastric ulcer (GU),&#xD;
                  Gastroesophageal reflux disease (GERD), impaction, chronic constipation,&#xD;
                  inflammatory bowel disease, ischemic colitis, vascular intestinal&#xD;
                  atherosclerosis, previous bowel resection, bowel obstruction, bariatric surgery,&#xD;
                  cholecystitis [including history of cholecystectomy], and/or appendectomy).&#xD;
&#xD;
               7. Positive result for H. pylori breath test at screening.&#xD;
&#xD;
               8. Had diarrhea or vomiting within 48 hours prior to check-in.&#xD;
&#xD;
               9. Has nasal abnormalities that could affect pH probe insertion.&#xD;
&#xD;
              10. Cannot tolerate placement of the pH probe.&#xD;
&#xD;
              11. Female participants with a positive pregnancy test at screening or check-in or&#xD;
                  who are lactating.&#xD;
&#xD;
              12. Positive urine drug or alcohol results at screening or check-in.&#xD;
&#xD;
              13. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
                  surface antigen (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
              14. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
                  screening.&#xD;
&#xD;
              15. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.&#xD;
&#xD;
              16. Fridericia's correction to the QT interval (QTcF) interval is &gt;460 msec (males)&#xD;
                  or &gt;470 msec (females) or has electrocardiogram (ECG) findings deemed abnormal&#xD;
                  with clinical significance by the PI or designee at screening.&#xD;
&#xD;
              17. Estimated creatinine clearance &lt;80 mL/min at screening.&#xD;
&#xD;
              18. The participant has serum creatinine &gt;1.22 mg/dL at screening or check-in.&#xD;
&#xD;
              19. Unable to refrain from or anticipates the use of:&#xD;
&#xD;
                    -  Any drug, including prescription and non-prescription medications, herbal&#xD;
                       remedies, or vitamin supplements beginning 14 days prior to the first dosing&#xD;
                       and throughout the study. Medication listed as part of acceptable birth&#xD;
                       control methods will be allowed. After randomization, acetaminophen (up to 2&#xD;
                       g per 24 hours) may be administered at the discretion of the PI or designee.&#xD;
                       Topical lidocaine may be administered for pH probe insertion. Hormone&#xD;
                       replacement therapy will also be allowed.&#xD;
&#xD;
                    -  Any drugs known to be significant inducers of CYP3A4/5, CYP1A2, and/or&#xD;
                       CYP2C19 for 28 days prior to the first dosing and throughout the study.&#xD;
                       Appropriate sources will be consulted by the PI or designee to confirm lack&#xD;
                       of PK / PD interaction with study drug.&#xD;
&#xD;
              20. Has been on a diet incompatible with the on-study diet, in the opinion of the PI&#xD;
                  or designee, within the 30 days prior to the first dosing and throughout the&#xD;
                  study.&#xD;
&#xD;
              21. Donation of blood or significant blood loss within 56 days prior to the first&#xD;
                  dosing.&#xD;
&#xD;
              22. Plasma donation within 7 days prior to the first dosing.&#xD;
&#xD;
              23. Participation in another clinical study within 30 days prior to the first dosing.&#xD;
                  The 30 day window will be derived from the date of the last blood collection or&#xD;
                  dosing, whichever is later, in the previous study to Day 1 of Period 1 of the&#xD;
                  current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Phathom Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion, 2420 W Baseline Rd,</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vonoprazan</keyword>
  <keyword>Lansoprazole</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

